Role for antimalarials in the management of COVID-19.

PURPOSE OF REVIEW The current review highlights recent insights into direct antiviral effects by antimalarials against severe acute respiratory syndrome (SARS)-CoV-2 and other viruses and their potential indirect effects on the host by avoiding exaggerated immune responses (reduced cytokine release, Toll-like receptor response, antigen presentation related to lysosomal processing). RECENT FINDINGS Currently, there is a large debate on the use of antimalarials for prophylaxis and treatment of SARS-CoV-2-induced disease based on preclinical in-vitro data, small case series and extrapolation from earlier studies of their effect on intracellular pathogens, including many viruses. Hydroxychloroquine (HCQ) or chloroquine have not demonstrated robust efficacy in prior randomized controlled studies against several other viruses. In-vitro data indicate a reduced viral replication of SARS-CoV-2. Especially immunomodulatory effects of antimalarials might also contribute to a clinical efficacy. For SARS-CoV-2 various large studies will provide answers as to whether antimalarials have a place in prophylaxis or treatment of the acute virus infection with SARS-CoV-2 but compelling data are missing so far. SUMMARY In-vitro data provide a theoretical framework for an efficacy of antimalarials in SARS-CoV-2-induced disease but clinical proof is currently missing.

[1]  B. Premack,et al.  Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. , 2000, Blood.

[2]  T. Bestebroer,et al.  Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.

[3]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[4]  W. Downie,et al.  Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis. , 1981, Annals of the rheumatic diseases.

[5]  H. Akpovwa.  Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity , 2016, Cell biochemistry and function.

[6]  J. Reveille,et al.  Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort , 2012, Lupus.

[7]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.

[8]  A. Flahault,et al.  On chikungunya acute infection and chloroquine treatment. , 2008, Vector borne and zoonotic diseases.

[9]  J. Dupouy-Camet,et al.  Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 , 2020, One Health.

[10]  B. Gazzard,et al.  Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. , 2012, JAMA.

[11]  Q. Bassat,et al.  In-Vivo Efficacy of Chloroquine to Clear Asymptomatic Infections in Mozambican Adults: A Randomized, Placebo-controlled Trial with Implications for Elimination Strategies , 2017, Scientific Reports.

[12]  Md Abdul Alim Al-Bari,et al.  Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases , 2015, The Journal of antimicrobial chemotherapy.

[13]  Tony Y. Hu,et al.  Insights from nanomedicine into chloroquine efficacy against COVID-19 , 2020, Nature Nanotechnology.

[14]  S. Bombardieri,et al.  COVID-19: the new challenge for rheumatologists. , 2020, Clinical and experimental rheumatology.

[15]  A. Phelan,et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.

[16]  M. Lederman,et al.  The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. , 2016, AIDS research and human retroviruses.

[17]  Christian Drosten,et al.  The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies , 2013, Journal of Virology.

[18]  C. Fiehn,et al.  Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review , 2020, Zeitschrift für Rheumatologie.

[19]  Marc Van Ranst,et al.  In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine , 2004, Biochemical and Biophysical Research Communications.

[20]  Sharon E. Miller,et al.  CALM Regulates Clathrin-Coated Vesicle Size and Maturation by Directly Sensing and Driving Membrane Curvature , 2015, Developmental cell.

[21]  J. Farrar,et al.  A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults , 2010, PLoS neglected tropical diseases.

[22]  Z. Zhao,et al.  Structure analysis of the receptor binding of 2019-nCoV , 2020, Biochemical and Biophysical Research Communications.

[23]  C. Page,et al.  Pharmacology of Heparin and Related Drugs , 2016, Pharmacological Reviews.

[24]  P. Ravaud,et al.  No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial , 2020, medRxiv.

[25]  Y. Cheung,et al.  Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. , 2011, The Lancet. Infectious diseases.

[26]  R. Chow,et al.  Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. , 1997, Clinical therapeutics.

[27]  Kathryn L. Schornberg,et al.  Ebola Virus and Severe Acute Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence that Transport to NPC1+ Endolysosomes Is a Rate-Defining Step , 2014, Journal of Virology.

[28]  G. Fonarow,et al.  Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. , 2020, JAMA cardiology.

[29]  C. Delaugerre,et al.  No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection , 2020, Médecine et Maladies Infectieuses.

[30]  D. Raoult,et al.  Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. , 1999, Archives of internal medicine.

[31]  D. Tang,et al.  Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. , 2013, Biochemical pharmacology.

[32]  L. Mayer,et al.  Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. , 1995, Clinical therapeutics.

[33]  P. Ferrante,et al.  The Use of Antimalarial Drugs against Viral Infection , 2020, Microorganisms.

[34]  E. McChesney,et al.  Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. , 1967, Toxicology and applied pharmacology.

[35]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[36]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  G. Olinger,et al.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies , 2017, Drugs.

[38]  Md. Abdul Alim Al-Bari.  Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases , 2017, Pharmacology research & perspectives.

[39]  Jiro Wada,et al.  MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells , 2018, PloS one.

[40]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[41]  I. Donatelli,et al.  Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses , 2007, Virology Journal.

[42]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[43]  D. Raoult,et al.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.

[44]  Alexis Jacquier,et al.  Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.

[45]  J. Singer,et al.  Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV‐infected patients receiving antiretroviral therapy , 2015, HIV medicine.

[46]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[47]  Gefei Wang,et al.  Chloroquine enhances replication of influenza A virus A/WSN/33 (H1N1) in dose‐, time‐, and MOI‐dependent manners in human lung epithelial cells A549 , 2015, Journal of medical virology.

[48]  E. Ooi,et al.  In vitro inhibition of human influenza A virus replication by chloroquine , 2006, Virology Journal.

[49]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[50]  M. Clerici,et al.  Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. , 2011, Blood.

[51]  A. Savarino.  Use of chloroquine in viral diseases , 2011, The Lancet Infectious Diseases.

[52]  V. Stecher,et al.  Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. , 1996, Clinical therapeutics.

[53]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[54]  E. Bonfá,et al.  Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome , 2014, Current opinion in rheumatology.

[55]  R. Grainger,et al.  A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 , 2020, Annals of Internal Medicine.

[56]  C. Conrad,et al.  SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. , 2020, The EMBO journal.

[57]  F. Fenton,et al.  Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19 , 2020, Heart Rhythm.

[58]  F. Fenollar,et al.  Whipple's disease. , 2007, The New England journal of medicine.